Sasaki T, Abiko N, Uchida H, Tanaka M, Nitta K, Yoshioka Y, Nomura H
Cancer Treat Rep. 1983 Mar;67(3):275-80.
The well-defined (1 leads to 3)-beta-D-glucan with DP (degree of polymerization) 540 and the various chain-length (1 leads to 3)-beta-D-glucans prepared by its hydrolysis were chemically modified to furanyl- and pyranyl-derivatives. As a primary screening, the effect of 20 derivatives thus obtained was tested on Sarcoma 180 solid tumor transplanted sc into allogeneic ICR mice; the dose was 10 mg/kg ip for 10 days. Eleven derivatives that showed a strong antitumor effect on Sarcoma 180 were also tested on Meth-A solid tumor in syngeneic mice. Of the derivatives tested, five furanyl-derivatives (F-4, F-6, F-7, F-10, and F-11) and one pyranyl-derivative (P-5) had potent antitumor effects on this syngeneic tumor system at ip doses of 10 or 30 mg/kg for 10 days. By oral administration, only two derivatives (F-10 and P-3) showed moderate antitumor activity against Sarcoma 180, without complete tumor regression. The mechanism of action of these derivatives was considered to be host-mediated and similar to that of the original glucan, because of a lack of effect in vitro.
将具有540聚合度(DP)的明确的(1→3)-β-D-葡聚糖及其水解制备的各种链长的(1→3)-β-D-葡聚糖化学修饰为呋喃基和吡喃基衍生物。作为初步筛选,测试了由此获得的20种衍生物对皮下移植到同种异体ICR小鼠体内的肉瘤180实体瘤的作用;剂量为腹腔注射10mg/kg,持续10天。对肉瘤180显示出强抗肿瘤作用的11种衍生物也在同基因小鼠的Meth-A实体瘤上进行了测试。在所测试的衍生物中,5种呋喃基衍生物(F-4、F-6、F-7、F-10和F-11)和1种吡喃基衍生物(P-5)在腹腔注射10或30mg/kg、持续10天的情况下,对这种同基因肿瘤系统具有强效抗肿瘤作用。通过口服给药,只有2种衍生物(F-10和P-3)对肉瘤180显示出中度抗肿瘤活性,但肿瘤未完全消退。由于这些衍生物在体外没有作用,其作用机制被认为是宿主介导的,并且与原始葡聚糖的作用机制相似。